Tianjin, China – July 28, 2022 – Genobio Pharmaceutical Co., Ltd, a wholly-owned subsidiary of Era Biology Group, which is a leader and pioneer of invasive fungal disease diagnostic field since 199...
A recent multi-center study on the diagnosis of cryptococcal infections was conducted by the Medical Center of Utrecht University, the Institute of Biodiversity and Ecosystem Dynamics of the Univer...
On June 7th, Era Biology hosted a live webinar for Latin America. The webinar focuses on antimicrobial resistance problem. Since 2005, the antibiotic resistance rate of bacteria has been increasing...
Tianjin, China – April 21, 2022 – Tianjin Era Biology Technology Co., Ltd is please to announce that Era Biology obtained registration certificates for all seven Carbapenem-resistant Detection K-Se...
FACIS Successfully Approved by Health Canada
We are glad to announce that the Full-Automatic Chemiluminescence Immunoassay System (FACIS), with its adaptable reagents the Aspergillus Galactomannan ...
YY/T 1729-2020 “Fungus (1-3)-β-D-Glucan Test” formulated by Era Biology was approved by NMPA on July 9, 2020 and officially released. The standard will be formally implemented on June 1...